The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
Most scalp serums are ineffective for hair loss, with Nécessaire’s “The Scalp Serum” being the only one showing noticeable results, though it's not worth the cost. For androgenetic alopecia, clinical treatments like minoxidil and finasteride are necessary, while caffeine and capixyl may offer some benefits.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
A female user is experiencing severe hair loss, especially at the crown and front, with broken and dull hair despite using Moroccan oil, shea moisture shampoo, and coconut oil. She seeks recommendations for a clinic or doctor as previous doctors attributed the issue to stress but offered no solutions.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
The conversation humorously discusses hair loss treatments, mentioning a regime of 1mg oral finasteride, 5% topical finasteride, and 1mg kryptonite. It also references the use of minoxidil for hair regrowth.
Topical melatonin was found to significantly increase hair density and decrease scalp conditions like seborrheic dermatitis. The user is considering using it alongside finasteride and oral minoxidil for treating hair loss and scalp health.
The conversation is about someone seeking a doctor in the EU who prescribes spironolactone or bicalutamide for female pattern hair loss, as they are having difficulty finding treatment options beyond Minoxidil in Austria. They are asking for recommendations and are open to direct messages for assistance.
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.
Minoxidil is on sale at Costco, but it poses a significant risk to pets, especially cats. Users discuss the pros and cons of foam versus liquid minoxidil, with some preferring liquid for better results despite its greasiness and dandruff issues.
The user plans to mix Kirkland minoxidil with spironolactone tablets for hair loss. They cannot use finasteride, saw palmetto, or spearmint tea due to side effects like insomnia and low testosterone.
A user in Egypt is seeking alternatives to oral minoxidil, which is banned there, after stopping topical minoxidil due to concerns for their cat's safety. Suggestions include drinking diluted topical minoxidil or making homemade minoxidil tablets, but these methods carry significant risks and are not recommended.
The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
A user named "tresslessinseattle" receiving a mysterious package of Eucapil hair loss treatment, which they are considering in combination with Minoxidil and Finasteride treatments to boost the regrowth they have been seeing.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).